AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29193943 — intervention group
Group type: EXPERIMENTAL
Intervention: Local steroids combined with therapeutic exercise at home
Number of subjects: 30
Study 29193943 — intervention group
Group type: COMPARATOR
Intervention: Conventional physical therapy (Control)
Number of subjects: 30
Study 26427112 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard DCXC therapy (2-g corbrin capsules, 3 times/d, 3 days before and after angiography)
Number of subjects: 120
Study 26427112 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive DCXC therapy (3-g corbrin capsules, 3 times/d, 3 days before and after angiography)
Number of subjects: 120
Study 26427112 — intervention group
Group type: COMPARATOR
Intervention: Basic treatment group
Number of subjects: 120
Study 26427112 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard DCXC therapy
Number of subjects: 120
Study 26427112 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive DCXC therapy
Number of subjects: 120
Study 25061764 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate-electrolyte solution (CES)
Number of subjects: 14
Study 25061764 — intervention group
Group type: COMPARATOR
Intervention: No fluid (NF)
Number of subjects: 14
Study 22693075 — intervention group
Group type: EXPERIMENTAL
Intervention: Dry mouth toothpaste
Number of subjects: 10
Study 22693075 — intervention group
Group type: COMPARATOR
Intervention: Fluoride toothpaste (placebo)
Number of subjects: 10
Study 20386004 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza vaccination
Number of subjects: 104
Study 20386004 — intervention group
Group type: COMPARATOR
Intervention: Placebo administration
Number of subjects: 104
Study 17157397 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolysis for acute myocardial infarction
Number of subjects: 44
Study 17157397 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers (control group)
Number of subjects: 44
Study 16354893 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial overdrive pacing (AOP)
Number of subjects: 16
Study 16354893 — intervention group
Group type: COMPARATOR
Intervention: Nasal continuous positive airway pressure (n-CPAP)
Number of subjects: 16
Study 12108534 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational interventions
Number of subjects: 27
Study 9472784 — intervention group
Group type: EXPERIMENTAL
Intervention: GR213487B liquid nasal spray (0.4375mg, 4.0mg, or 0.0625mg)
Number of subjects: 12
Study 9472784 — intervention group
Group type: COMPARATOR
Intervention: Lipid alone (control)
Number of subjects: 12
Study 8543620 — intervention group
Group type: EXPERIMENTAL
Intervention: Flow cytometry analysis for FMH quantitation
Number of subjects: 43
Study 8543620 — intervention group
Group type: EXPERIMENTAL
Intervention: Flow cytometry analysis leading to anti-D immunoglobulin administration
Number of subjects: 43
Study 8543620 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up testing for immunisation
Number of subjects: 43
Study 2227107 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (25 mg twice daily)
Number of subjects: 64
Study 2227107 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine AR (20 mg twice daily)
Number of subjects: 64
Study 2227107 — intervention group
Group type: COMPARATOR
Intervention: Placebo (1 tablet twice daily)
Number of subjects: 64
Study 415359 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 15
Study 415359 — intervention group
Group type: EXPERIMENTAL
Intervention: Cromolyn (Lomudal)
Number of subjects: 15
Study 415359 — intervention group
Group type: COMPARATOR
Intervention: Control (no placebo)
Number of subjects: 15
Study 30635033 — intervention group
Group type: EXPERIMENTAL
Intervention: Clazakizumab (subcutaneous administration of 25 mg in monthly intervals)
Number of subjects: 20
Study 30635033 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 25439076 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep duration 7 to <8 hours
Number of subjects: 391
Study 25439076 — intervention group
Group type: COMPARATOR
Intervention: Sleep duration <6 hours
Number of subjects: 391
Study 25439076 — intervention group
Group type: COMPARATOR
Intervention: Sleep duration ≥9 hours
Number of subjects: 391
Study 22765511 — intervention group
Group type: COMPARATOR
Intervention: Conventional brackets
Number of subjects: 38
Study 22765511 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-ligating brackets
Number of subjects: 38
Study 22765511 — intervention group
Group type: EXPERIMENTAL
Intervention: Both bracket types
Number of subjects: 38
Study 21386797 — intervention group
Group type: EXPERIMENTAL
Intervention: Very Low-Calorie Diet (VLCD)
Number of subjects: 24
Study 19317863 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine with 0.5 microg/kg neostigmine
Number of subjects: 75
Study 19317863 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine with 0.75 microg/kg neostigmine
Number of subjects: 75
Study 19317863 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine with 1 microg/kg neostigmine
Number of subjects: 75
Study 19317863 — intervention group
Group type: COMPARATOR
Intervention: Plain 0.5% hyperbaric bupivacaine
Number of subjects: 75
Study 16740529 — intervention group
Group type: EXPERIMENTAL
Intervention: Off-pump coronary artery bypass surgery
Number of subjects: 168
Study 16740529 — intervention group
Group type: COMPARATOR
Intervention: Conventional coronary artery bypass grafting surgery using cardiopulmonary bypass
Number of subjects: 168
Study 15250864 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventricular triad (RV ‐‐> SVC + Can)
Number of subjects: 58
Study 15250864 — intervention group
Group type: COMPARATOR
Intervention: Unipolar (RV ‐‐> Can)
Number of subjects: 58
Study 15250864 — intervention group
Group type: COMPARATOR
Intervention: Proximal triad (SVC ‐‐> RV + Can)
Number of subjects: 58
Study 15250864 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximal triad
Number of subjects: 58
Study 11262468 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic antibiotics
Number of subjects: 7
Study 9305202 — intervention group
Group type: EXPERIMENTAL
Intervention: Normothermic perfusion (37 degrees C)
Number of subjects: 300
Study 9305202 — intervention group
Group type: COMPARATOR
Intervention: Hypothermia (28 degrees C)
Number of subjects: 300
Study 9305202 — intervention group
Group type: COMPARATOR
Intervention: Moderate hypothermia (32 degrees C)
Number of subjects: 300
Study 8359292 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose acetylsalicylic acid (ASA, 75 mg daily)
Number of subjects: 232
Study 8359292 — intervention group
Group type: COMPARATOR
Intervention: Placebo (identical tablets)
Number of subjects: 232
Study 3521832 — intervention group
Group type: EXPERIMENTAL
Intervention: 3,150 rads of preoperative radiotherapy
Number of subjects: 361
Study 3521832 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone (Control)
Number of subjects: 361
Study 3521832 — intervention group
Group type: EXPERIMENTAL
Intervention: First preoperative radiotherapy trial
Number of subjects: 361
Study 3521832 — intervention group
Group type: COMPARATOR
Intervention: First preoperative radiotherapy trial (Control)
Number of subjects: 361
Study 29371264 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-supported self-management programme
Number of subjects: 89
Study 29371264 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 89
Study 27247434 — intervention group
Group type: EXPERIMENTAL
Intervention: COBRA (prednisolone 60 mg/day, tapered to 7.5 mg/day in 6 weeks; MTX and SSZ)
Number of subjects: 108
Study 27247434 — intervention group
Group type: EXPERIMENTAL
Intervention: COBRA-light therapy (prednisolone 30 mg/day, tapered to 7.5 mg/day in 8 weeks and MTX)
Number of subjects: 108
Study 26291644 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative projective story‐telling technique (Düss Fable)
Number of subjects: 0
Study 26291644 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative data (Child Behaviour Checklist)
Number of subjects: 0
Study 23317049 — intervention group
Group type: EXPERIMENTAL
Intervention: SCTG plus EMD
Number of subjects: 42
Study 23317049 — intervention group
Group type: COMPARATOR
Intervention: SCTG
Number of subjects: 42
Study 21134017 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeinated alcoholic beverage (69 mg caffeine/12 oz beer)
Number of subjects: 127
Study 21134017 — intervention group
Group type: COMPARATOR
Intervention: Non-caffeinated alcoholic beverage
Number of subjects: 127
Study 19052516 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioengineered skin substitutes with a dermal component
Number of subjects: 0
Study 19052516 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 16750341 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative ultrasound technique (QUS) at the phalanges
Number of subjects: 73
Study 16750341 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-dialytic and non-fractured women)
Number of subjects: 73
Study 12875936 — intervention group
Group type: EXPERIMENTAL
Intervention: Flutamide or Cyproterone acetate
Number of subjects: 257
Study 11853591 — intervention group
Group type: EXPERIMENTAL
Intervention: Phacotrabeculectomy with IOL implantation
Number of subjects: 68
Study 11853591 — intervention group
Group type: COMPARATOR
Intervention: ECCE, trabeculectomy and IOL implantation
Number of subjects: 68
Study 9092738 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsaicin 0.025% cream
Number of subjects: 0
Study 9092738 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 1487551 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil (120 mg three times daily for 3 days)
Number of subjects: 0
Study 1487551 — intervention group
Group type: COMPARATOR
Intervention: Acute volume expansion (1500 mL saline in 15 minutes, in supine legs-up position)
Number of subjects: 0
Study 1487551 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil with volume expansion
Number of subjects: 0
Study 3021488 — intervention group
Group type: COMPARATOR
Intervention: Nedocromil sodium (4 mg) q.i.d.
Number of subjects: 167
Study 3021488 — intervention group
Group type: COMPARATOR
Intervention: Nedocromil sodium (4 mg) b.i.d.
Number of subjects: 167
Study 3021488 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 167
Study 31186047 — intervention group
Group type: EXPERIMENTAL
Intervention: Oleogel-S10
Number of subjects: 0
Study 31186047 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 28315450 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotenoid supplementation (Macushield™: 10 mg meso-zeaxanthin, 10 mg lutein, 2 mg zeaxanthin)
Number of subjects: 37
Study 28315450 — intervention group
Group type: COMPARATOR
Intervention: Placebo (sunflower oil)
Number of subjects: 37
Study 25824243 — intervention group
Group type: EXPERIMENTAL
Intervention: rhGH (47.6-52.4 μg/kg/day) and low-dose stanozolol (20-35 μg/kg/day)
Number of subjects: 44
Study 25824243 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 44
Study 24317497 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based psychoeducational program (Diapason), 12 weeks duration, weekly sessions
Number of subjects: 80
Study 24317497 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control condition)
Number of subjects: 80
Study 22310865 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal relationship program (10 sessions over 10 weeks, 90 minutes each)
Number of subjects: 64
Study 22310865 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 64
Study 19484836 — intervention group
Group type: EXPERIMENTAL
Intervention: Vascular care (treatment according to strict guidelines for hypercholesterolemia and hypertension, including acetylsalicylic acid, folic acid, and pyridoxine)
Number of subjects: 130
Study 19484836 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 130
Study 19484836 — intervention group
Group type: EXPERIMENTAL
Intervention: Vascular care
Number of subjects: 130
Study 17251237 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic CPAP
Number of subjects: 34
Study 17251237 — intervention group
Group type: COMPARATOR
Intervention: Sham CPAP
Number of subjects: 34
Study 17251237 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic CPAP (in CPAP-compliant patients)
Number of subjects: 34
Study 15027793 — intervention group
Group type: EXPERIMENTAL
Intervention: Free association task
Number of subjects: 41
Study 15027793 — intervention group
Group type: COMPARATOR
Intervention: Describing most stressful life experience
Number of subjects: 41
Study 14709288 — intervention group
Group type: EXPERIMENTAL
Intervention: Brimonidine tartrate 0.2% drops 2 times a day
Number of subjects: 40
Study 14709288 — intervention group
Group type: COMPARATOR
Intervention: Placebo (artificial tears)
Number of subjects: 40
Study 9640158 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiopental 5 mg kg‐1 (AT‐R group)
Number of subjects: 60
Study 9640158 — intervention group
Group type: EXPERIMENTAL
Intervention: Etomidate 0.3 mg kg‐1 (AE‐R group)
Number of subjects: 60
Study 7569161 — intervention group
Group type: EXPERIMENTAL
Intervention: External cephalic version with tocolysis
Number of subjects: 45
Study 7569161 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 45
Study 3055394 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative parenteral cefoxitin (Group A)
Number of subjects: 350
Study 3055394 — intervention group
Group type: COMPARATOR
Intervention: Preoperative oral neomycin and erythromycin plus perioperative cefoxitin (Group B)
Number of subjects: 350
Study 3055394 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (cefoxitin) with rectal resections
Number of subjects: 350
Study 3055394 — intervention group
Group type: COMPARATOR
Intervention: Group B (neomycin and erythromycin plus cefoxitin) with rectal resections
Number of subjects: 350
Study 3055394 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (cefoxitin) with intraperitoneal colon resection
Number of subjects: 350
Study 3055394 — intervention group
Group type: COMPARATOR
Intervention: Group B (neomycin and erythromycin plus cefoxitin) with intraperitoneal colon resection
Number of subjects: 350
Study 3055394 — intervention group
Group type: COMPARATOR
Intervention: Group B patients with longer rectal operations
Number of subjects: 350
Study 3055394 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A patients with longer rectal operations
Number of subjects: 350
Study 3055394 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with rectal resection and operative times of 215 minutes or more
Number of subjects: 350
Study 3055394 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with shorter nonrectal operations
Number of subjects: 350
Study 3055394 — intervention group
Group type: COMPARATOR
Intervention: Group B patients
Number of subjects: 350
Study 4592210 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive end expiratory pressure (PEEP) of 10 cm H2O added to intermittent positive pressure ventilation (IPPV)
Number of subjects: 8
Study 4592210 — intervention group
Group type: COMPARATOR
Intervention: Intermittent positive pressure ventilation (IPPV) without PEEP
Number of subjects: 8
Study 31124422 — intervention group
Group type: EXPERIMENTAL
Intervention: In-person follow-up group (IN-FU), n=200
Number of subjects: 400
Study 31124422 — intervention group
Group type: COMPARATOR
Intervention: Telephone follow-up group (TEL-FU), n=200
Number of subjects: 400
Study 31124422 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 400
Study 30920631 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptococcus salivarius 24SMB and Streptococcus oralis 89a nasal spray, 2 puffs per nostril twice a day for a week for 3 months
Number of subjects: 44
Study 30920631 — intervention group
Group type: COMPARATOR
Intervention: Hypertonic saline nasal lavage
Number of subjects: 44
Study 29042389 — intervention group
Group type: EXPERIMENTAL
Intervention: Trainees
Number of subjects: 1749
Study 29042389 — intervention group
Group type: COMPARATOR
Intervention: Consultants
Number of subjects: 1749
Study 29042389 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 1749
Study 25425002 — intervention group
Group type: EXPERIMENTAL
Intervention: RT-ATM
Number of subjects: 47
Study 25425002 — intervention group
Group type: EXPERIMENTAL
Intervention: RT-LTM
Number of subjects: 47
Study 25425002 — intervention group
Group type: COMPARATOR
Intervention: RT
Number of subjects: 47
Study 23925369 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Number of subjects: 24
Study 23925369 — intervention group
Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 24
Study 21125336 — intervention group
Group type: EXPERIMENTAL
Intervention: uPA system gene polymorphisms (specifically PAI-1 gene)
Number of subjects: 253
Study 21125336 — intervention group
Group type: EXPERIMENTAL
Intervention: Environmental carcinogens (betel nut and tobacco consumption)
Number of subjects: 253
Study 21125336 — intervention group
Group type: EXPERIMENTAL
Intervention: uPAR gene polymorphism
Number of subjects: 253
Study 20465019 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel nasal EPAP device
Number of subjects: 34
Study 17123215 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific intervention programme for endurant pain coping behavior (n = 163)
Number of subjects: 415
Study 17123215 — intervention group
Group type: COMPARATOR
Intervention: Standard programme of an orthopaedic rehabilitation clinic (n = 252)
Number of subjects: 415
Study 15016040 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-mouth scaling and root planing (FM-SRP)
Number of subjects: 40
Study 15016040 — intervention group
Group type: COMPARATOR
Intervention: Quadrant scaling and root planing (Q-SRP)
Number of subjects: 40
Study 11323362 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural infusion of ropivacaine 2 mg/mL with fentanyl 2 microg/mL (R + F)
Number of subjects: 155
Study 11323362 — intervention group
Group type: COMPARATOR
Intervention: Epidural infusion of ropivacaine 2 mg/mL without fentanyl (R)
Number of subjects: 155
Study 9302489 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (EX; 20 min of cycling at 60% estimated VO2max)
Number of subjects: 28
Study 9302489 — intervention group
Group type: COMPARATOR
Intervention: Normal workstation duties for 60 min (WRK)
Number of subjects: 28
Study 9302489 — intervention group
Group type: COMPARATOR
Intervention: 60 min sedentary lunch break (SED)
Number of subjects: 28
Study 8394796 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril 10 mg administered at 7 AM
Number of subjects: 8
Study 8394796 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril 10 mg administered at 7 PM
Number of subjects: 8
Study 3205554 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% lidocaine (xylocaine) containing 1:80,000 epinephrine
Number of subjects: 12
Study 3205554 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% prilocaine (Citanest) containing 0.03 IU/ml felypressin
Number of subjects: 12
Study 31158553 — intervention group
Group type: EXPERIMENTAL
Intervention: tDCS plus FES
Number of subjects: 30
Study 31158553 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS plus FES
Number of subjects: 30
Study 29583063 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-pass pulsed dye laser (SWL)
Number of subjects: 21
Study 29583063 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-pass pulsed dye laser (DWL)
Number of subjects: 21
Study 29583063 — intervention group
Group type: COMPARATOR
Intervention: Untreated control
Number of subjects: 21
Study 28468736 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotinamide 500 mg/daily
Number of subjects: 38
Study 28468736 — intervention group
Group type: COMPARATOR
Intervention: Control group (no nicotinamide)
Number of subjects: 38
Study 25727519 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibular taping with tension
Number of subjects: 21
Study 25727519 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibular taping without tension
Number of subjects: 21
Study 23816035 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational video intervention
Number of subjects: 59
Study 23816035 — intervention group
Group type: COMPARATOR
Intervention: Usual care (health care provider counseling)
Number of subjects: 59
Study 21435142 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 130
Study 21435142 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 130
Study 18492867 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive renal-replacement therapy (intermittent hemodialysis six times per week, sustained low-efficiency dialysis, continuous venovenous hemodiafiltration at 35 ml/kg/hour)
Number of subjects: 1124
Study 18492867 — intervention group
Group type: COMPARATOR
Intervention: Less-intensive renal-replacement therapy (intermittent hemodialysis three times per week, continuous renal-replacement therapy at 20 ml/kg/hour)
Number of subjects: 1124
Study 18492867 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive renal-replacement therapy
Number of subjects: 1124
Study 18492867 — intervention group
Group type: COMPARATOR
Intervention: Less-intensive renal-replacement therapy
Number of subjects: 1124
Study 17055449 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural approach
Number of subjects: 48
Study 17055449 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem-solving approach
Number of subjects: 48
Study 15572533 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza vaccination
Number of subjects: 696
Study 15572533 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 696
Study 11239191 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture (including electroacupuncture)
Number of subjects: 150
Study 11239191 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation (high-intensity, low-frequency)
Number of subjects: 150
Study 11239191 — intervention group
Group type: COMPARATOR
Intervention: Subliminal electrostimulation (control group)
Number of subjects: 150
Study 9225646 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic treatment
Number of subjects: 105
Study 9225646 — intervention group
Group type: COMPARATOR
Intervention: Conventional conservative abdominal surgery (Laparotomy)
Number of subjects: 105
Study 9225646 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 105